Navigation Links
MedCath Corporation Reports First Quarter Earnings
Date:2/7/2008

d $0.2 million, or $0.01 per diluted share, in the first quarter of fiscal 2008. MedCath did not incur pre-opening expenses in the first quarter of fiscal 2007. Adjusted EBITDA in this release does not include share-based compensation expense or pre-opening expenses, but these expenses are included as a component of income from continuing operations.

"We experienced a strong start to fiscal 2008, driven by strategic and operating initiatives upon which we embarked two years ago and that are the foundation for our successes in this and previous quarters," said O. Edwin French, MedCath's president and chief executive officer. "Our hospitals had strong inpatient and outpatient volumes, and our operating initiatives allowed us to expand our Adjusted EBITDA and increase our EPS during the quarter."

Operating Statistics and Cash Flow

Same facility hospital adjusted admissions for the first quarter of fiscal 2008 increased 6.4% from the first quarter of the previous fiscal year. Same facility hospital net revenue increased 4.6% after adjusting first quarter of 2007's revenue for a reimbursement adjustment that reduced net revenue by $2.7 million. Net cash provided by operating activities of continuing operations for the first quarter of fiscal 2008 was $0.7 million, down from $11.4 million for the first quarter of fiscal 2007. This decrease was due to the payment of a previously announced $5.8 million settlement between one of MedCath's hospitals and the United States Department of Justice and a $9.2 million increase in cash tax payments during the first quarter of fiscal 2008 in comparison to the first quarter of fiscal 2007.

Capital expenditures, including $4.6 million in expenditures related to MedCath's growth initiatives, totaled $14.3 million in the first quarter of fiscal 2008 in comparison to $3.5 million in the first quarter of fiscal 2007.

Use of Non-GAAP Financial Measures

This release contains measures of MedCath's hist
'/>"/>

SOURCE MedCath Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. MedCath Corporation to Hold Conference Call on First Quarter Results
2. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
3. MedCath Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
4. MedCath Corporation Reports Fourth Quarter Earnings and Outlook for Fiscal 2008
5. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
6. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
7. Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management
8. CRH Medical Corporation announces substantial increase in patient visits
9. Medical Simulation Corporation and the American Board of Internal Medicine Introduce New Simulation for Physician Assessment and Evaluation
10. Providence Service Corporation to Present at the 2008 UBS Global Healthcare Services Conference on February 11
11. Triple-S Management Corporation to Present at UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... the adenoids and tonsils, is performed 500,000 times a ... for children with obstructive sleep apnea. However, the ... functioning, behavior, sleep apnea symptoms, and quality of life ... study led by Susan Redline, MD, MPH, director ... Associate Clinic Director of the Division of Sleep Medicine ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution and http://HRA Link: ... Zane Benefits’ website, the Affordable Care Act (known as ... 2010 and impacts many areas of health care and ...
(Date:5/21/2013)... 2013 A new study appearing in ... that stem cells harvested from fat (adipose) are more ... to modulate the body’s immune system. , The ... therapies, as adipose tissue-derived stem cells (AT-SCs) are far ... bone marrow and can be collected from waste material ...
(Date:5/21/2013)... 21, 2013 Octo Consulting Group, ... management consulting solutions to the Federal marketplace, has ... In the newly created role, Denny will ... of the firm’s business development function to include ... functions, and leading strategies to achieve the firm’s ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... Department of Antiquities of Syria and the University of Chicago ... fought in upper Mesopotamia// in 3500 B.C., leading to the ... that the entire area where the excavation was conducted was ... by the archeologists. Hamoukar is in Syria at the Iraqi ...
... related to Food science and consumer acceptance in Norway ... then do experts to cheese.// ,The food compared ... with expert dairy assessors. The rating was based on ... ,There was difference of opinion in both factions. As ...
... will be spending $60 million to buy 1.8 courses ... //Australian Health Minister Tony Abbott confirmed the order yesterday. ... to pharmaceuticals giant GlaxoSmithKline, but Biota had alleged that ... this allegation. This fresh order makes it the third ...
... has been conducted on a six-year-old Pakistani boy at the ... his birthday on 19 December 2005. //,Anupam Sibal, Medical Director ... in ICU but is responding well to medication. Doctors are ... be normal soon.' , ,He refused to give further ...
... Yoga, Acupuncture, Ayurveda, Chinese movement therapies such as ... just some of the commonly used alternative treatments ... Europe. //Perhaps, this is because it’s strongly perceived ... treatment for cancer with the combination of some ...
... of James Cook University's (JCU) has urged the Health ... the University which will help to produce more doctors ... graduation day.// James Cook University is Australia's premier tropical ... The University is named after the British explorer, Captain ...
Cached Medicine News:Health News:Excavations Reveal Clues Of Early Warfare 2
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... May 21, 2013  Janssen R&D Ireland (Janssen) ... the global Phase 3 PROMISE study demonstrating that ... led to sustained virologic response 12 weeks after ... of treatment-experienced genotype 1 chronic hepatitis C adult ... of liver fibrosis, when administered once daily with ...
Breaking Medicine Technology:Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... Disease Week data highlight effects of AMITIZA in ... ... results indicated that,treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant ... were presented at Digestive Disease Week (DDW) 2008, the,largest annual international ...
... Five Oral Presentations at ASCO Annual Meeting Will Further ... Front-line Multiple Myeloma -, CAMBRIDGE, Mass., May 16 ... new data from VELCADE,clinical studies are scheduled to be ... Annual Meeting in Chicago, Illinois, May 30 -,June 3, ...
Cached Medicine Technology:New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
... system was expressly designed to obtain the ... special source and an equally special power ... particular high energy impulses with constant peak ... 'top-flat shaped') allow storage of enough energy ...
... Derm is a KTP laser, very compact ... nm (frequency doubled Nd:YAG) for dermatologic treatments. ... comfortable color LCD Touch-screen. Maximum power ... 0.3, 0.5, 0.7 and 1.0 mm. SmartLite ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
... is the result of DEKA s ... of three different methods capable of ... skin. This treatment is designed to ... through the combined action of a ...
Medicine Products: